72: Treatment outcomes with tyrosine kinase inhibitors in patients with uncommon EGFR mutations in non-small cell lung cancer
Sarah Hunter(Guy's and St Thomas' NHS Foundation Trust), Eleni Karapanagiotou(King's College London), James Spicer(King's College London), S. Merrick, Guillermina Nickless(Guy's Hospital), D. Smith, Rohit Lal, Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Soma Ghosh(Center for Devices and Radiological Health)
Cited by 0
Related Papers
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
|The Lancet Oncology|2021|614
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
|Clinical Cancer Research|2021|567
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
|The Lancet Oncology|2019|228